利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

56 条记录 (耗时 0.043 秒)

    COMPOUNDS THAT MODULATE HSP90 ACTIVITY AND METHODS FOR IDENTIFYING SAME
    3.
    发明申请
    COMPOUNDS THAT MODULATE HSP90 ACTIVITY AND METHODS FOR IDENTIFYING SAME 审中-公开
    调节HSP90活性的化合物和用于鉴定其的方法

    公开(公告)号：WO2007139960A3

    公开(公告)日：2008-03-20

    申请号：PCT/US2007012529

    申请日：2007-05-25

    申请人： SYNTA PHARMACEUTICALS CORP ,  YING WEIWEN

    发明人： YING WEIWEN

    IPC分类号： C07D249/12 ,  C07D405/06

    CPC分类号： G01N33/57415 ,  C07D249/12 ,  C07D401/04 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D405/06 ,  C07D413/04 ,  C07D417/04 ,  C07D487/04 ,  G01N2500/04

    摘要： The present invention relates to compositions and methods related to inhibitors of Hsp90, including substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in heed thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound. The invention further provides methods for designing and identifying inhibitors of Hsp90.

    摘要翻译： 本发明涉及与Hsp90抑制剂有关的组合物和方法，包括取代的三唑化合物和包含取代的三唑化合物的组合物。 本发明还涉及抑制有需要的受试者中Hsp90的活性的方法以及在受试者中预防或治疗过度增殖性疾病如癌症的方法，其包括向受试者施用本发明的取代的三唑化合物， 或包含这种化合物的组合物。 本发明还提供了用于设计和鉴定Hsp90抑制剂的方法。

    METHOD FOR THE PREPARATION OF TRIAZOLE COMPOUNDS WITH HSP90 MODULATING ACTIVITY
    4.
    发明申请
    METHOD FOR THE PREPARATION OF TRIAZOLE COMPOUNDS WITH HSP90 MODULATING ACTIVITY 审中-公开
    用HSP90调节活性制备三唑化合物的方法

    公开(公告)号：WO2007139952A3

    公开(公告)日：2008-03-13

    申请号：PCT/US2007012520

    申请日：2007-05-25

    申请人： SYNTA PHARMACEUTICALS CORP ,  LEE CHI-WAN ,  JAMES DAVID ,  ZHANG SHIJIE ,  YING WEIWEN ,  CHIMMANAMADA DINESH U ,  CHAE JUNGHYUN ,  PRZEWLOKA TERESA

    发明人： LEE CHI-WAN ,  JAMES DAVID ,  ZHANG SHIJIE ,  YING WEIWEN ,  CHIMMANAMADA DINESH U ,  CHAE JUNGHYUN ,  PRZEWLOKA TERESA

    IPC分类号： C07D249/12 ,  C07D249/14 ,  C07D403/04

    CPC分类号： C07D403/04 ,  C07D249/12 ,  C07D249/14 ,  C07D401/04 ,  C07D401/10 ,  C07D403/10 ,  C07D413/04 ,  C07D417/04

    摘要： The present invention provides novel methods of preparing triazole compounds which inhibit the activity of Hsp90. One embodiment of the invention is directed to methods for preparing a triazole compound represented by the following Structural Formula: or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof, comprising the steps of: a) reacting an amide represented by the following Structural Formula: with a thionation reagent to form a thioamide; b) reacting the thioamide of step a) with hydrazine to form a hydrazonamide; c) reacting the hydrazonamide of step b) with a carbonylation or a thiocarbonylation reagent. In one embodiment, the present invention is a method of synthesis of a compound of formula (IA) or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof, comprising reacting a compound of formula (IIA) with an oxidizing agent, thereby producing a compound of formula (IA). The present invention is also directed to a method of preparing a compound or a tautomer thereof represented by the following Structural Formula: (IB) or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof. The method comprises the step of reacting a first starting compound represented by the following Structural Formula: (HB) in the presence of a mercuric salt, with a second starting compound represented by the following Structural Formula: (IIIB).

    摘要翻译： 本发明提供抑制Hsp90活性的三唑化合物的新方法。 本发明的一个实施方案涉及制备由以下结构式表示的三唑化合物或互变异构体，药学上可接受的盐，溶剂合物或包合物或其前药的方法，其包括以下步骤：a）使酰胺 由以下结构式表示：用硫化试剂形成硫代酰胺; b）使步骤a）的硫代酰胺与肼反应形成腙酰胺; c）使步骤b）的腙与羰基化或硫代羰基化试剂反应。 在一个实施方案中，本发明是合成式（IA）化合物或互变异构体，其药学上可接受的盐，溶剂合物或包合物或其前药的方法，包括使式（IIA）化合物与 氧化剂，从而制备式（IA）化合物。 本发明还涉及由以下结构式：（IB）或互变异构体，其药学上可接受的盐，溶剂合物或包合物或其前药代表的化合物或其互变异构体的制备方法。 该方法包括使由以下结构式：（HB）表示的第一起始化合物在汞盐存在下与由以下结构式：（IIIB）表示的第二起始化合物反应的步骤。

    PYRAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY
    6.
    发明申请
    PYRAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY 审中-公开
    调节HSP90活性的吡咯化合物

    公开(公告)号：WO2007021966A1

    公开(公告)日：2007-02-22

    申请号：PCT/US2006/031430

    申请日：2006-08-10

    申请人： SYNTA PHARMACEUTICALS CORP. ,  YING, Weiwen ,  ZHANG, Shijie ,  DU, Zhenjian ,  FOLEY, Kevin

    发明人： YING, Weiwen ,  ZHANG, Shijie ,  DU, Zhenjian ,  FOLEY, Kevin

    IPC分类号： C07D231/18 ,  C07D231/20 ,  C07D403/04 ,  C07D231/38 ,  A61K31/415 ,  A61P35/00

    CPC分类号： C07D231/20 ,  C07D231/18 ,  C07D231/38 ,  C07D403/04

    摘要： Compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I) and methods of inhibiting Hsp90 in a cell, treating or preventing a proliferation disorder in a mammal and treating cancer in a mammal comprising administering a compound of formula (I) to a patient or a cell. Variable R 5 is an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a subslituent R 18 , defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in addition to R 3 . Substituent R 3 is defined herein.

    摘要翻译： 式（I）化合物，包含式（I）化合物的药物组合物和抑制细胞中Hsp90的方法，治疗或预防哺乳动物中的增殖病症并在哺乳动物中治疗癌症，包括给予式（I）化合物至 患者或细胞。 可变的R 5是任选取代的杂芳基; 任选取代的6至14元芳基; 任选在任何可取代的氮或碳原子上取代的双环9元杂环; 或本文定义的取代基R 18。 环A是任选地进一步被一个或多个取代基除了R 3 3进一步取代的芳基或杂芳基。 取代基R 3在本文中定义。